Free Trial
→ Why I went to Mount Rushmore (From Stansberry Research) (Ad)tc pixel
NASDAQ:RNAC

Cartesian Therapeutics Earnings Date & Estimates

Cartesian Therapeutics logo
$7.05 +0.23 (+3.37%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$7.08 +0.03 (+0.43%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cartesian Therapeutics is expected to report earnings on Thursday, November 5, 2026, before market opens.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Announcement Date
Time
Before Market Opens
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Cartesian Therapeutics

Cartesian Therapeutics is expected to post earnings of -$1.02 per share on revenue of $0.16 million. In the same quarter a year earlier Cartesian Therapeutics reported -$1.38 per share on revenue of $0.45 million. Cartesian Therapeutics last reported on August 6, 2026, posting $0.46 per share and beating the -$0.8779 consensus estimate. Cartesian Therapeutics has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$1.02
Expected Revenue
$0.16 million
Prior-Year EPS
-$1.38
Prior-Year Revenue
$0.45 million
Expected Revenue Growth
-64.6%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.46 (Beat by +$1.3379)
EPS Beat Rate
3 of last 8 quarters

Prepare for the Earnings Call

Cartesian Therapeutics Earnings FAQ

Cartesian Therapeutics (NASDAQ:RNAC) is estimated to report earnings on Thursday, November 5, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect Cartesian Therapeutics to post earnings of -$1.02 per share for the quarter.

The consensus revenue estimate for Cartesian Therapeutics is $0.16 million for the quarter.

Cartesian Therapeutics Earnings Headlines

Cartesian Therapeutics Announces New Employment Inducement Grants
October 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/02/3373738/0/en/cartesian-therapeutics-announces-new-employment-inducement-grants.html
Cartesian Therapeutics (NASDAQ:RNAC) Stock Rating Reaffirmed as "Buy" by HC Wainwright
October 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31077110
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe calls it The 10-Minute Guide to Start Trading Options Today, built to help you open your first options trade with less capital than buying shares outright.tc pixel
October 10 at 1:00 AM  |  True Market Insiders (Ad)
Needham & Company LLC Reaffirms "Buy" Rating for Cartesian Therapeutics (NASDAQ:RNAC)
October 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31071935
Cartesian Reports Positive Phase 2 Retreatment Data For Descartes-08
September 29, 2026  |  rttnews.comhttps://www.rttnews.com/3694809/cartesian-reports-positive-phase-2-retreatment-data-for-descartes-08.aspx
Cartesian's Descartes-08 Shows Durable Responses In Myasthenia Gravis
September 29, 2026  |  rttnews.comhttps://www.rttnews.com/3694799/cartesian-s-descartes-08-shows-durable-responses-in-myasthenia-gravis.aspx
See More Cartesian Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cartesian Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cartesian Therapeutics and other key companies, straight to your email.

About Cartesian Therapeutics

Cartesian Therapeutics (NASDAQ:RNAC) is a clinical-stage biotechnology company focused on developing mRNA cell therapies for autoimmune diseases. The company’s platform is designed to genetically program a patient’s own T cells with messenger RNA, enabling the development of transiently engineered cell therapies that may be administered without permanent genetic modification.

Cartesian’s lead product candidate is Descartes-08, an autologous anti-BCMA CAR T-cell therapy being developed for autoimmune conditions, including generalized myasthenia gravis and systemic lupus erythematosus. The candidate is intended to target antibody-producing plasma cells that contribute to disease activity.

Headquartered in Gaithersburg, Maryland, Cartesian conducts clinical development activities and trials primarily through the U.S. healthcare and biotechnology ecosystem. The company became publicly traded under the NASDAQ symbol RNAC following a 2024 business combination with Selecta Biosciences. Carsten Brunn serves as Cartesian’s president and chief executive officer.

View Cartesian Therapeutics Profile
Earnings Tools